Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Multiple Ascending Dose Study of R1507 in Patients With Advanced Solid Tumors.
- First Posted Date
- 2006-11-16
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 98
- Registration Number
- NCT00400361
A Long Term Extension of Study NC19453 Evaluating Safety and Efficacy of RO4607381
Phase 2
Completed
- Conditions
- Coronary Heart Disease
- Interventions
- Drug: placebo
- First Posted Date
- 2006-11-16
- Last Posted Date
- 2020-01-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 77
- Registration Number
- NCT00400439
The Effect Of Oral Ibandronate In Male Osteoporosis
- First Posted Date
- 2006-11-10
- Last Posted Date
- 2009-12-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 135
- Registration Number
- NCT00397839
- Locations
- 🇺🇸
GSK Investigational Site, Madison, Wisconsin, United States
A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients
Phase 3
Completed
- Conditions
- Anemia
- Interventions
- Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
- First Posted Date
- 2006-11-02
- Last Posted Date
- 2017-01-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 490
- Registration Number
- NCT00394953
A Study of Induction Dosing With PEGASYS (Peginterferon Alfa-2a [40KD]) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C
Phase 4
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2006-10-31
- Last Posted Date
- 2010-08-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1175
- Registration Number
- NCT00394277
A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Phase 3
Completed
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2006-10-23
- Last Posted Date
- 2015-08-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 424
- Registration Number
- NCT00391092
A Study of Aleglitazar in Patients With Type 2 Diabetes
Phase 2
Completed
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- First Posted Date
- 2006-10-17
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 332
- Registration Number
- NCT00388518
A Drug-Drug Interaction Study of GK Activator (2) and Glyburide in Patients With Type 2 Diabetes.
Phase 1
Completed
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- Drug: GK Activator (2)
- First Posted Date
- 2006-10-17
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 18
- Registration Number
- NCT00388986
A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS With or Without COPEGUS in Patients With Chronic Hepatitis C (CHC) Genotype 1 Infection.
Phase 2
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2006-09-18
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 107
- Registration Number
- NCT00377182
COMFORT Study: A Crossover Study of NeoRecormon (Epoetin Beta) and Darbepoetin Alfa in Patients With Renal Anemia.
- First Posted Date
- 2006-09-18
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 48
- Registration Number
- NCT00377481
© Copyright 2025. All Rights Reserved by MedPath